Diffuse Diabetic Macular Edema
Conditions
Interventions
Initially, both eyes of each patient received 1.25mg/0.05ml of intravitreal injection of bevacizumab. One eye then received 20mg/0.5ml of subtenon injection of triamcinolone acetonide at the onset, an
Sponsors
NTT East Japan Tohoku Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type II diabetic patients whose bilateral DDME with foveal thickness greater than 400 micrometer and with logMAR visual acuity worse than 0.3
Exclusion criteria
Exclusion criteria: Eyes with severe proliferative retinopathy were excluded from the study. Patients with a history of focal or pan retinal photocoagulation and/or cataract surgery in either eye within the 6 months prior to entry into the study, and patients who had previous therapies for DDME, including grid laser treatment, intravitreal injection of any drugs, and/or vitreous surgery, were excluded from this study. Patients with systemic disorders other than hypertension and hypercholesterolemia were excluded from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Foveal thickness were monitored monthly for 1-year. The total number of intravitreal injections of bevacizumab injections during the follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| logMAR visual acuity and intraocular pressure | — |
Countries
Japan
Contacts
Public ContactMasahiko Shimura
Tokyo Medical University Hachioji Medical Center Department of Ophthalmology
Outcome results
None listed